JP
Jazz Pharmaceuticals plc is a global biopharmaceutical company founded in 2003 in Palo Alto, California. The company is dedicated to discovering, developing, and commercializing innovative medicines that address unmet medical needs in neuroscience, oncology, and rare diseases. Since its merger with Azur Pharma plc in 2011, Jazz has been headquartered in Dublin, Ireland, and focuses on creating life-changing therapies for serious conditions. The company has a diverse portfolio of marketed medicines, including Xyrem and Xywav for narcolepsy, as well as treatments for epilepsy and various cancers. Jazz has expanded its offerings through strategic acquisitions, including Celator Pharmaceuticals and GW Pharmaceuticals, and maintains a robust research and development pipeline. Their operations emphasize patient-centric innovation, regulatory compliance, and global commercialization, ensuring that they meet the needs of patients with serious health challenges.
http://www.linkedin.com/company/jazz-pharmaceuticals
http://www.jazzpharma.com